Adherence to metformin demonstrated a significant reduction in the risk of developing dementia. This data was consistent across both male and female patients, ages >65 or ≤ 65 years, and those with or without concurrent insulin treatment. Metformin adherence had no significant association with the development of PD. Here, INS is linked to Parkinson disease.